Class III antiarrhythmics: Potassium channel blockers

Last updated: September 05, 2022

Class III antiarrhythmics: Potassium channel blockers

cardio

cardio

Introduction to the cardiovascular system
Introduction to the lymphatic system
Cardiovascular system anatomy and physiology
Coronary circulation
Lymphatic system anatomy and physiology
Abnormal heart sounds
Normal heart sounds
Baroreceptors
Chemoreceptors
Renin-angiotensin-aldosterone system
Cardiac cycle
Cardiac work
Changes in pressure-volume loops
Pressure-volume loops
Cardiac and vascular function curves
Altering cardiac and vascular function curves
Cardiac afterload
Cardiac contractility
Cardiac preload
Frank-Starling relationship
Law of Laplace
Measuring cardiac output (Fick principle)
Stroke volume, ejection fraction, and cardiac output
Physiological changes during exercise
Cardiovascular changes during hemorrhage
Cardiovascular changes during postural change
Cardiac conduction velocity
Cardiac conduction system
ECG basics
ECG normal sinus rhythm
ECG intervals
ECG QRS transition
ECG axis
ECG rate and rhythm
ECG cardiac infarction and ischemia
ECG cardiac hypertrophy and enlargement
Control of blood flow circulation
Microcirculation and Starling forces
Blood pressure, blood flow, and resistance
Compliance of blood vessels
Laminar flow and Reynolds number
Pressures in the cardiovascular system
Resistance to blood flow
Action potentials in myocytes
Action potentials in pacemaker cells
Cardiac excitation-contraction coupling
Excitability and refractory periods
Adrenergic antagonists: Beta blockers
Calcium channel blockers
cGMP mediated smooth muscle vasodilators
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
ACE inhibitors, ARBs and direct renin inhibitors
Thiazide and thiazide-like diuretics
Lipid-lowering medications: Fibrates
Lipid-lowering medications: Statins
Miscellaneous lipid-lowering medications
Positive inotropic medications
Atrioventricular block
Bundle branch block
Pulseless electrical activity
Atrial fibrillation
Atrial flutter
Atrioventricular nodal reentrant tachycardia (AVNRT)
Premature atrial contraction
Wolff-Parkinson-White syndrome
Brugada syndrome
Long QT syndrome and Torsade de pointes
Premature ventricular contraction
Ventricular fibrillation
Ventricular tachycardia
Endocarditis
Myocarditis
Rheumatic heart disease
Cardiac tumors
Dilated cardiomyopathy
Hypertrophic cardiomyopathy
Restrictive cardiomyopathy
Atrial septal defect
Coarctation of the aorta
Patent ductus arteriosus
Ventricular septal defect
Hypoplastic left heart syndrome
Tetralogy of Fallot
Total anomalous pulmonary venous return
Transposition of the great vessels
Persistent truncus arteriosus
Cor pulmonale
Heart failure
Cardiac tamponade
Dressler syndrome
Pericarditis and pericardial effusion
Shock
Arterial disease
Aneurysms
Aortic dissection
Angina pectoris
Coronary steal syndrome
Myocardial infarction
Prinzmetal angina
Stable angina
Unstable angina
Abetalipoproteinemia
Familial hypercholesterolemia
Hyperlipidemia
Hypertriglyceridemia
Conn syndrome
Cushing syndrome
Hypertension
Hypertensive emergency
Pheochromocytoma
Polycystic kidney disease
Renal artery stenosis
Hypotension
Orthostatic hypotension
Lymphangioma
Lymphedema
Peripheral artery disease
Subclavian steal syndrome
Nutcracker syndrome
Superior mesenteric artery syndrome
Angiosarcomas
Human herpesvirus 8 (Kaposi sarcoma)
Vascular tumors
Behcet's disease
Kawasaki disease
Vasculitis
Chronic venous insufficiency
Deep vein thrombosis
Thrombophlebitis
Acyanotic congenital heart defects: Pathology review
Aortic dissections and aneurysms: Pathology review
Atherosclerosis and arteriosclerosis: Pathology review
Cardiac and vascular tumors: Pathology review
Cardiomyopathies: Pathology review
Coronary artery disease: Pathology review
Cyanotic congenital heart defects: Pathology review
Dyslipidemias: Pathology review
Endocarditis: Pathology review
Heart blocks: Pathology review
Heart failure: Pathology review
Hypertension: Pathology review
Pericardial disease: Pathology review
Peripheral artery disease: Pathology review
Shock: Pathology review
Supraventricular arrhythmias: Pathology review
Valvular heart disease: Pathology review
Vasculitis: Pathology review
Ventricular arrhythmias: Pathology review
Arteriole, venule and capillary histology
Artery and vein histology
Cardiac muscle histology
Development of the cardiovascular system
Fetal circulation
Anatomy of the coronary circulation
Anatomy of the heart
Anatomy of the inferior mediastinum
Anatomy of the superior mediastinum
Anatomy clinical correlates: Heart
Anatomy clinical correlates: Mediastinum
Introduction to pharmacology
Chest X-ray interpretation: Clinical sciences
Electrolyte disturbances: Pathology review
Anatomy clinical correlates: Breast
Anticoagulants: Heparin
Thrombolytics
Congestive heart failure: Clinical sciences
Approach to ascites: Clinical sciences
Approach to dyspnea: Clinical sciences
Approach to lower limb edema: Clinical sciences
Coronary artery disease: Clinical sciences
Chronic obstructive pulmonary disease: Clinical sciences
Tobacco use: Clinical sciences
Approach to chest pain: Clinical sciences
Approach to hypertension: Clinical sciences
Acute coronary syndrome: Clinical sciences
Carotid artery stenosis screening: Clinical sciences
Diabetes mellitus (Type 1): Clinical sciences
Diabetes mellitus (Type 2): Clinical sciences
Dyslipidemia: Clinical sciences
Essential hypertension: Clinical sciences
Peripheral arterial disease and ulcers: Clinical sciences
Abdominal aortic aneurysm: Clinical sciences
Aortic dissection: Clinical sciences
Approach to bradycardia: Clinical sciences
Approach to postoperative hypotension: Clinical sciences
Approach to tachycardia: Clinical sciences
Atrioventricular block: Clinical sciences
Cardiac tamponade: Clinical sciences
Central line-associated bloodstream infection: Clinical sciences
Hypovolemic shock: Clinical sciences
Infectious endocarditis: Clinical sciences
Pericarditis: Clinical sciences
Ventricular tachycardia: Clinical sciences

Transcript

Watch video only

Antiarrhythmic medications help control arrhythmias, or abnormal heart beats.

There are five main groups of antiarrhythmic medications: class I, also known as sodium-channel blockers; class II, also called beta-blockers; class III, also known as potassium-channel blockers; class IV, also called calcium-channel blockers; and miscellaneous antiarrhythmics, or unclassified antiarrhythmics. Now, we’ll focus on class III antiarrhythmic medications.

Normally, an electrical signal starts at the sinoatrial or SA node in the right atrium, then propagates out through both atria, making them contract.

The signal gets delayed a bit as it goes through the atrioventricular or AV node, then goes through the Bundle of His to the Purkinje fibers of both ventricles, making them contract as well.

When the signal doesn’t follow this pathway, we get abnormal heartbeats called an arrhythmia, and there are two main causes - abnormal automaticity and abnormal reentry.

Abnormal automaticity is when an area of the heart, say, a part of the ventricle, begins to fire off action potentials at a rate that’s even faster than the SA node.

As a result, this area of the heart essentially flips roles with the SA node, firing so fast that the pacemaker cells in the SA node don’t get a chance to fire. At that point, the heartbeat is being driven by the ventricles.

Alternatively, there can be an abnormal reentry which often results from scar tissue in a ventricle after a heart attack.

Scar tissue doesn’t conduct electricity, so the signal just goes around and around the scar, and each cycle can cause the ventricles to contract.

Alternatively, there might be an accessory, or extra pathway between the atria and the ventricles, like the bundle of Kent in Wolff-Parkinson-White syndrome.

Here, the signal might move back up the accessory pathway, since oftentimes it’s bidirectional, meaning the signal can go from atrium to ventricle as well as from ventricle to atrium.

This creates a reentry circuit that causes extra contractions that occur in between the signals coming from the SA node.

Now let’s focus on a single action potential in a myocyte - it can be broken into five phases.

Here’s a graph of the membrane potential vs. time. In phase 4, which is the resting phase, the myocyte’s membrane slowly depolarizes. This is caused by the leakage of some ions - mainly calcium ions - through the gap junctions, which are openings between two neighboring cells, and that makes the membrane depolarize to the threshold potential, which marks the start of phase 0.

Phase 0 is the depolarization phase where voltage gated sodium channels open up when they reach the threshold potential, and they allow sodium to rush into the cell, creating an inward current. This rapid influx of sodium causes the myocyte’s membrane potential to become more positive.

After the membrane has depolarized, we enter Phase 1, initial repolarization. At this point the sodium channels close and the voltage-gated potassium channels open up, allowing positive potassium ions to leave the cell. This is called the outward current and the membrane potential starts to fall, and this creates a little notch on our graph.

Soon, there’s phase 2 or the plateau phase, which is when the voltage-gated calcium channels open up, and that allows positively charged calcium ions into the cell which counterbalances the potassium ions that are flowing out, so the membrane potential remains pretty stable.

During phase 3, or repolarization, the calcium channels close, but the potassium channels remain open, resulting in a net outward positive current. At the same time, ion pumps start to pump calcium ions back out of the cell and that causes the heart to relax.

Eventually the myocyte returns to the resting membrane potential and we start over with phase 4 again.

Now, class III antiarrhythmics bind and inhibit potassium (K+) channels, which are responsible for repolarization during phase 3 of the action potential in cardiomyocytes. These channels are also called cardiac delayed rectifier potassium channels, or IKr.

So, when they’re blocked, there’s less potassium leaving the cell, which leads to a slower rate of repolarization.

Ultimately, this results in the prolonged duration of action potentials and effective refractory periods, which is the period of time that the cell is unexcitable by new stimulus. On the ECG, this shows up as a longer Q-T interval.

So, longer repolarization prevents the fast conduction of the action potential throughout the heart, which eventually leads to a slower heart rate!

But, since class III antiarrhythmics prolong the QT interval, they can trigger a type of arrhythmia called torsade de pointes, which means “the twisting of points,” because the QRS complexes seem to twist around the isoelectric line.

Common medications in this class include amiodarone, dronedarone, sotalol, ibutilide, and dofetilide.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Therapeutic drug monitoring: antiarrhythmic drugs" British Journal of Clinical Pharmacology (1998)
  4. "Effects of amiodarone on short QT syndrome variant 3 in human ventricles: a simulation study" BioMedical Engineering OnLine (2017)
  5. "Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy" Vascular Health and Risk Management (2010)
  6. "Dronedarone for the treatment of atrial fibrillation and atrial flutter" Health Technology Assessment (2010)
  7. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)